Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 9.36% is 150% above its 5-year average of -18.74%, around the middle of its 5-year range (-51.38%–36.95%).
6.85% above its 12-month average of 8.76%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 18.39%.
RETURN ON ASSETS (ROA)
9.36%
RETURN ON ASSETS (ROA) AVG TTM
8.76%
RETURN ON ASSETS (ROA) AVG 3Y
-13.98%
RETURN ON ASSETS (ROA) AVG 5Y
-18.74%
RETURN ON ASSETS (ROA) AVG 10Y
-32.03%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.85%
CURRENT VS 3Y AVG
+166.95%
CURRENT VS 5Y AVG
+149.96%
CURRENT VS 10Y AVG
+129.22%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+129.01%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.92B
Return on Assets (ROA)
9.36%
TTM Avg
8.76%
3Y Avg
-13.98%
5Y Avg
-18.74%
Market Cap
$8.93B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$8.97B
Return on Assets (ROA)
-25.17%
TTM Avg
-38.54%
3Y Avg
-43.55%
5Y Avg
-63.00%
Market Cap
$8.72B
Return on Assets (ROA)
-18.21%
TTM Avg
-20.38%
3Y Avg
-22.99%
5Y Avg
-19.64%
Market Cap
$8.67B
Return on Assets (ROA)
-15.15%
TTM Avg
-26.36%
3Y Avg
-26.24%
5Y Avg
-23.50%
Market Cap
$9.21B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$9.33B
Return on Assets (ROA)
11.86%
TTM Avg
10.65%
3Y Avg
7.37%
5Y Avg
5.11%
Market Cap
$8.38B
Return on Assets (ROA)
4.91%
TTM Avg
-3.24%
3Y Avg
-6.85%
5Y Avg
-10.42%
Market Cap
$9.63B
Return on Assets (ROA)
-33.91%
TTM Avg
-19.19%
3Y Avg
-22.29%
5Y Avg
-23.79%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.92B | 9.36% | 8.76% | -13.98% | -18.74% |
| Bruker Corporation (BRKRP)vs › | $8.93B | -1.18% | 0.91% | 5.02% | 5.47% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | -25.17% | -38.54% | -43.55% | -63.00% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | -18.21% | -20.38% | -22.99% | -19.64% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | -15.15% | -26.36% | -26.24% | -23.50% |
| Bruker Corporation (BRKR)vs › | $9.21B | -1.18% | 0.91% | 5.02% | 5.47% |
| Insulet Corp. (PODD)vs › | $9.33B | 11.86% | 10.65% | 7.37% | 5.11% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 4.91% | -3.24% | -6.85% | -10.42% |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | -33.91% | -19.19% | -22.29% | -23.79% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 16.09% | 11.90% | 0.02% | -3.56% |
ROA
9.4%
ROE
9.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -19.43% |
| 2024-12-31 | 36.95% |
| 2023-12-31 | -22.06% |
| 2022-12-31 | -51.38% |
| 2021-12-31 | -36.11% |
| 2020-12-31 | -20.39% |
| 2019-12-31 | -49.82% |
| 2018-12-31 | -27.91% |
| 2017-12-31 | -22.57% |
| 2016-12-31 | -39.55% |
| 2015-12-31 | -100.09% |
| 2014-12-31 | -107.20% |
